The Riga Virus is the first virotherapy medication in the world that has been approved for clinical use. In 2004 it was registered in Latvia for the treatment of malignant melanoma. In 2015 the medication was approved in Georgia and in 2016 it was approved in Armenia. It is the only clinically approved non-genetically modified oncolytic virus in the world. Virotherapy with the Riga Virus prolongs a patient’s recurrence-free period, prolongs a patients' life and improves quality of life.
The medication is currently fully subsidised by the state for Latvian patients suffering from malignant melanoma and it is included in clinical guidelines approved by the National Health Service of Latvia. In 2016, the manufacturer of this medication received a grant from the European Commission’s "Horizon 2020" sub-programme "Aid for biotechnologies to promote new product sales in the European market" with the intended goal of eventually registering the medication for sale in the European Union (EMEA).
The medication is injected directly into a patient’s muscle in accordance with tailor-made treatment protocols. Usually treatment takes place on an out-patient basis with only minimal side effects. The most common side effect is a slightly increased body temperature lasting for one to three days.
For more information visit the website www.rigvir.com
← Go back